1053659-39-4 Usage
General Description
3-Bromo-6-chloropicolinonitrile, 97% is a specialized chemical compound with a high level of purity, as indicated by the 97% in its name. The compound is part of the larger family of picolinonitriles, which are a series of heterocyclic organic compounds containing a pyridine ring bearing a cyano group and a bromo group at the 3rd and 6th positions respectively. They are primarily used in research and development settings, where they contribute to a wide range of scientific and industrial applications. Due to the presence of bromine and chlorine atoms, the compound displays unique chemical properties. Its applications can include the synthesis of various pharmaceuticals, agrochemicals, and other complex organic molecules. Handling and use of such chemicals necessitates a firm understanding of safety procedures due to their reactivity and potential hazards.
Check Digit Verification of cas no
The CAS Registry Mumber 1053659-39-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,5,3,6,5 and 9 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1053659-39:
(9*1)+(8*0)+(7*5)+(6*3)+(5*6)+(4*5)+(3*9)+(2*3)+(1*9)=154
154 % 10 = 4
So 1053659-39-4 is a valid CAS Registry Number.
1053659-39-4Relevant articles and documents
Homogenous suspension of immunopotentiating compounds and uses thereof
-
, (2016/09/12)
The present invention generally relates to homogeneous suspensions of small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject in need thereof. The homogeneous suspensions may be used in combinations with various antigens or adjuvants for vaccine therapies.
COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS
-
, (2009/10/22)
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X3 is N; X4 is N Or CR3; X5 is -CR4=CR5.